Clinical Updates

Enrollment Closure -- Trial 1182.58: An Open-Label Safety Study (OLSS)

From American Academy of HIV Medicine

Fall 2004

Trial 1182.58 evaluates the safety of tripranavir plus ritonavir when used in combination with other agents for the treatment of patients with HIV who have failed and/or are intolerant to combination antiretroviral therapy and have limited treatment options. The enrollment of new patients in the OLSS will cease once the tipranavir EAP initiates. Enrollment in the OLSS will remain open only for patients ages 13 to
Back to The Nexus Fall 2004 contents page.

This article was provided by American Academy of HIV Medicine. It is a part of the publication The Nexus.

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

Donna Summer, Coming Out, and How AIDS Changed It All: A Blog Entry by Mark S. King

Buffalo Bills Player Tweets HIV Test Results: Over-Share or Encouraging? A Blog Entry by Kellee Terrell

Study Finds HIV Infection Is an Independent Risk Factor for Lung Cancer

Broad-Spectrum Antivirals: The Future of HIV Treatment?

How Did I Get Here?

More >>

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.